The Boston Globe, June 22, 2023: FDA has approved Sarepta’s gene therapy for Duchenne muscular dystrophy, which will cost $3.2 million per patient. FDA’s Peter Marks praises the drug as if he is a Sarepta salesman, and NCHR explains why this political compromise is harmful to patients.
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
Pricey Alzheimer’s Drug Coverage Hinges on FDA Decision
Bloomberg News, June 15, 2023: If Leqembi is approved, it will take time for doctors to arrange for patients to be tested for mild cognitive impairment and amyloid plaques on the brain, get the Leqembi infusions, and sign up patients for a registry. NCHR praises the CMS Registry as a good choice, but industry-funded groups complain.
Read More »US FDA adcom supports Leqembi for full approval
BioWorld, June 9, 2023: BioWorld news explains that FDA Advisory Committee supports Leqembi for Mild Cognitive Impairment (MCI) caused by Alzheimer’s and quotes our statement that MCI can go away without drugs, which means that Leqembi’s risks of brain swelling and bleeding will often greatly outweigh the potential benefits.
Read More »Lilly battling rivals for breast-cancer patients
Indianapolis Business Journal, June 9, 2023: We explain to the Indianapolis Business Journal that 3 drug companies are spending $millions to persuade breast cancer patients that their drug is best despite risky side effects. Their ads are confusing and misleading.
Read More »Medicare outlines plan to expand coverage for costly new Alzheimer’s drugs
Washington Post, June 1, 2023: CMS announces that Medicare will cover FDA fully approved Alzheimer’s treatments for patients in a registry that will evaluate safety and efficacy. NCHR explains why this is essential to learn which patients are most likely to benefit and which are most likely to be harmed.
Read More »